本頁只刊出中文翻譯與中文說明；英文原文請見下方原文連結。
原文連結
論文資訊
- 類型：已發表論文
- 日期：2014-02-28
摘要
Objective Methotrexate (MTX) is the drug of first choice for the treatment of rheumatoid arthritis (RA), but is effective only in around 60% of the patients. Identification of 遺傳 markers to predict response is essential for effective treatment within a critical window period of 6 months after diagnosis, but have been hitherto elusive. In this study, we used 基因組-wide genotype data to identify the potential risk variants associated with MTX (poor)response in a north Indian RA cohort. Materials and methods 基因組-wide genotyping data for a total of 457 RA patients [297 good (DAS28-3 <= 3.2) and 160 poor (DAS28-3 >= 5.1) responders] on MTX monotherapy were tested for association using an additive model. Support vector machine and 基因組-wide pathway analysis were used to identify additional risk var
※ 此為已發表論文，全文需透過期刊付費取得